Hepatitis C Genotypes 2008
July-June
12- Versus 24-week Treatment with Pegylated
Interferon plus Ribavirin for Genotype 2 or 3 Chronic Hepatitis C
Patients
-
7/11/08
Studies Explore Lower Doses of Pegylated Interferon
and Ribavirin for People with Hepatitis C Virus Genotypes 2 or 3
-
Adequate Ribavirin Exposure
after the First Dose Predicts Sustained Virological Response to Hepatitis C
Treatment in Genotype 1 Patients
HCV Genotype 1 Patients
with High Viral Load Do Better with 48 vs 24 Weeks of Treatment, despite
Rapid Virological Response
-
7/04/08
Determining HCV Treatment Success: Early Response
Trumps Genotype
Longer Treatment Recommended for Genotype 6
Complete genome of a European hepatitis C virus
subtype 1g isolate: phylogenetic and genetic analyses
A randomized, prospective trial of ribavirin 400 mg/day versus 800 mg/day in
combination with peginterferon alfa-2a in hepatitis C virus genotypes 2 and
3
Response to Controlled-release Interferon Alfa-2b (Locteron)
in Genotype 1 Hepatitis C Patients
Safety and Activity of Once-Monthly Albinterferon
Alfa-2b (Albuferon) in Genotype 2/3 Chronic Hepatitis C Patients
Randomized comparison of 12 or 24 weeks of peginterferon a-2a and ribavirin
in chronic hepatitis C virus genotype 2/3 infection
-
Antiviral Activity, Pharmacodynamics, and Quality
of Life in Genotype 1 Hepatitis C Patients Treated with Albinterferon (Albuferon)
Amino Acid Substitutions in HCV Core Region Predict
Poor Response to Pegylated Interferon/ribavirin
in Genotype 1b Patients
Limitations of an 8-week Course of Pegylated
interferon plus Ribavirin for Genotype 2 Hepatitis C Patients with Rapid
Virological Response
FACTORS PREDICTIVE OF RELAPSE IN GENOTYPE 2 AND 3 PTS
TREATED FOR 12 WEEKS WITH PEGIFN ALFA 2B AND WEIGHT BASED RIBAVIRIN
COMBINATION -
RIBAVIRIN CONCENTRATION AT WEEK FOUR IS AN INDEPENDEND
PREDICTOR FOR SUSTAINED VIROLOGICAL RESPONSE AFTER TREATMENT OF HEPATITIS C
GENOTYPE 2/3 (NORDYNAMIC TRIAL) -
Vertex and Tibotec Start Phase 3 Study of Telaprevir
for Treatment-Naive Genotype 1 Hepatitis C Patients
Factors Predicting Relapse in Patients with
Genotype 2/3 HCV Treated with Pegylated Interferon plus Ribavirin
April-May
Telaprevir plus Pegylated Interferon and Ribavirin
Allows Shorter Therapy for Patients with Genotype 1 HCV
Vertex Announces Positive Interim Results
with Telaprevir-based Therapy in Genotype 1 Chronic Hepatitis C Patients who
Failed to Achieve SVR with Previous Pegylated Interferon & Ribavirin
Treatment
Telaprevir-Based PROVE Studies Show
Significantly Higher SVR Rates in Treatment-Naive Genotype 1 Hepatitis C
Patients in Half the Time of Current Treatments
March-February
Genetic Variations in HCV Genotype 3 Core Protein
Promote Liver Fat Accumulation
-
Asians with HCV Genotype 3 Do Not Respond as Well as
Caucasians to Interferon-based Therapy
Insulin Resistance Linked to Lower Treatment Response
in Genotype 2/3 Patients
Liver Steatosis Is Common in Hepatitis C Patients,
Especially Those with Genotype 3
Duration of Pegylated Interferon plus Ribavirin for
HCV Genotypes 2 and 3
-
January
Shorter HCV treatment shows notable success
An Updated Report on Hepatitis C Genotypes
Pegylated Interferon plus Ribavirin in the Treatment
of Chronic Hepatitis C Genotype 4
Insulin resistance and response to therapy in patients infected with chronic
hepatitis C virus genotypes 2 and 3 -
Hepatitis C genotype change after successful treatment
indicates re-infection
2007
2006
2005 Index Genotype Research
2004 Thru 2001 Index of all Genotype Research
|
